UNIGE document Scientific Article - Review
previous document  unige:19580  next document
add to browser collection

The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum

Sirima, Sodiomon B.
Tiono, Alfred B.
Gansane, Adama
Diarra, Amidou
Ouedraogo, Amidou
Konate, Amadou T.
Kiechel, Jean René
Morgan, Caroline C.
show hidden authors show all authors [1 - 10]
Published in Malaria Journal. 2009, vol. 8, 48
Abstract BACKGROUND: Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested. METHODS: A randomized, open-label trial was conducted comparing the efficacy (non-inferiority design) and safety of fixed (F) dose AS (25 mg)/AQ (67.5 mg) to loose (L) AS (50 mg) + AQ (153 mg) in 750, P. falciparum-infected children from Burkina Faso aged 6 months to 5 years. Dosing was by age. Primary efficacy endpoint was Day (D) 28, PCR-corrected, parasitological cure rate. Recipients of rescue treatment were counted as failures and new infections as cured. Documented, common toxicity criteria (CTC) graded adverse events (AEs) defined safety. RESULTS: Recruited and evaluable children numbered 750 (375/arm) and 682 (90.9%), respectively. There were 8 (AS/AQ) and 6 (AS+AQ) early treatment failures and one D7 failure (AS+AQ). Sixteen (AS/AQ) and 12 (AS+AQ) patients had recurrent parasitaemia (PCR new infections 10 and 6, respectively). Fourteen patients per arm required rescue treatment for vomiting/spitting out study drugs. Efficacy rates were 92.1% in both arms: AS/AQ = 315/342 (95% CI: 88.7-94.7) vs. AS+AQ = 313/340 (95% CI: 88.6-94.7). Non-inferiority was demonstrated at two-sided alpha = 0.05: Delta (AS+AQ - AS/AQ) = 0.0% (95% CI: -4.1% to 4.0%). D28, Kaplan Meier PCR-corrected cure rates (all randomized children) were similar: 93.7% (AS/AQ) vs. 93.2% (AS+AQ) Delta = -0.5 (95% CI -4.2 to 3.0%). By D2, both arms had rapid parasite (F & L, 97.8% aparasitaemic) and fever (97.2% [F], 96.0% [L] afebrile) clearances.Both treatments were well tolerated. Drug-induced vomiting numbered 8/375 (2.1%) and 6/375 (1.6%) in the fixed and loose arms, respectively (p = 0.59). One patient developed asymptomatic, CTC grade 4 hepatitis (AST 1052, ALT 936). Technical difficulties precluded the assessment and risk of neutropaenia for all patients. CONCLUSION: Fixed dose AS/AQ was efficacious and well tolerated. These data support the use of this new fixed dose combination for treating P. falciparum malaria with continued safety monitoring. TRIAL REGISTRATION: Current Controlled Trials ISRCTN07576538.
Keywords Amodiaquine/administration & dosage/adverse effects/*therapeutic useAnimalsAntimalarials/administration & dosage/adverse effects/*therapeutic useArtemisinins/administration & dosage/adverse effects/*therapeutic useBurkina FasoChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantKaplan-Meier EstimateMalaria, Falciparum/*drug therapyMaleParasitemia/drug therapyPlasmodium falciparum/*drug effectsPolymerase Chain ReactionTreatment Outcome
PMID: 19291301
Full text
Article - public document Free access
(ISO format)
SIRIMA, Sodiomon B. et al. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. In: Malaria Journal, 2009, vol. 8, p. 48. doi: 10.1186/1475-2875-8-48 https://archive-ouverte.unige.ch/unige:19580

459 hits



Deposited on : 2012-04-23

Export document
Format :
Citation style :